Dallas, TX (PRWEB) November 24, 2013
Restricted by the health care system and the medical inspection level (Chinese firms mainly lag behind foreign counterparts in molecular diagnostics and other special tests), Chinese independent clinical laboratory market only values RMB2.5-3 billion, equivalent to 2-3 percent of the total revenue of medical diagnosis, much lower than 30 percent in developed countries.
However, in the context of Chinese medical reform, the cost control of public hospitals, the increasing number of patients that primary medical institutions are confronted with, the rapid development of private hospitals and other factors will greatly boost China independent clinical laboratory industry which will grow at a rate over 40 percent.
Complete report is available at http://www.chinamarketresearchreports.com/113103.html.
The report focuses on the operation, advantages and characteristics of 10 major independent clinical laboratory companies in China on the basis of an analysis on the development environment, the market situation, the competition pattern, the impact of upstream and downstream as well as the prospect of China independent clinical laboratory industry.
In China, among about 110 laboratories engaged in independent medical diagnosis, top four ones, namely Kingmed Diagnostics, ADICON, DiAn Diagnostics and DaAn Health, master more than 70 percent domestic market share together, all with the chain integrated diagnostic service mode.
As a giant in China independent clinical laboratory industry, Kingmed Diagnostics has maintained a revenue growth rate of more than 50 percent in the past five years. It achieved the revenue of over RMB1 billion in 2012 with 21 laboratories, over 13,000 clients (including more than 1,000 Grade-A hospitals) and 1,600 types of inspec
Copyright©2012 Vocus, Inc.
All rights reserved